| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption
TEL AVIV, Israel, March 17, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced positive results from a pre-clinical trial as part of its ongoing collaboration agreement with Clearmind Medicine Inc. (CSE:CMND), (OTC:CMNDF), (FSE: CWY0). Results showed a significant dose dependent effect for the MEAI treatment in reducing alcohol consumption of the treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose.
Results showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01;) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg and compared to consumption before treatment. The mice were provided with 20% alcohol solution, for 24 hours, three times a week, for 7 weeks, and were treated everyday with MEAI or MEAI/CannAmide™ during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly in parallel.
Oz Adler, SciSparc's Chief Executive Officer, commented, "We are excited about these positive results, demonstrating the value added of achieving efficiency in lower doses. The Company's previous studies of CannAmide™ confirmed that the addition of CannAmideTM to various cannabinoids, such as THC and CBD, reduced the effective dose of the cannabinoid while maintaining its therapeutic effect. We plan to further explore opportunities in psychedelics market while we continue pursuing our current ongoing cannabinoid based clinical programs".
